Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results